Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Cystic Fibrosis: An Overview

4. Market Dynamics
   4.1 Drivers
         4.1.1 Robust Pipeline
         4.1.2 Rising Prevalence of Cystic Fibrosis
         4.1.3 Rising Life expectancy of Cystic Fibrosis Patient’s
         4.1.4 Improvement in Diagnostic Technologies
         4.1.5 Increasing Awareness
         4.1.6 Unmet Medical Needs
    4.2 Restraints
          4.2.1 Cystic Fibrosis Related Complications
          4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
          4.2.3 High Cost
    4.3 Opportunities
          4.3.1 Patent Expiry of Biggest-Selling Drugs
          4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis

5. Global Cystic Fibrosis Therapeutics Market Outlook 2022

6. Major Marketed Products
    6.1 Orkambi (lumacaftor/ivacaftor)
    6.2 Kalydeco (Ivacaftor)
    6.3 Cayston (Inhaled Aztreonam)
    6.4 Pulmozyme (Dornase Alfa)
    6.5 TOBI
    6.6 Creon
    6.7 Zenpep
    6.8 Ventolin
    6.9 Bronchitol (Inhaled Mannitol)
    6.10 ADEKplusTM
    6.11 Ibuprofen

7. Market Segmentation by Pharmacological Class
    7.1 CFTR modulators
    7.2 Mucolytic Agents
    7.3 Pancreatic Enzyme Replacement Products
    7.4 Antibiotics
    7.5 Other Therapies

8. Market Segmentation by Drug Molecule
    8.1 Small Molecule
    8.2 Biologic Drugs

9. Market Segmentation by Cystic Fibrosis Mutation Type
    9.1 Commercialized
          9.1.1 Class I
          9.1.2 Class II
          9.1.3 Class III
    9.2 Non-Commercialized
          9.2.1 Class IV
          9.2.2 Class V
          9.2.3 Class VI

10. Market Segmentation by Geography
      10.1 North America
      10.2 Europe
      10.3 Asia Pacific

11. Industry Trends & Developments
      11.1 Genetic Testing
      11.2 Technological Advances
      11.3 CFTR Modulators - Gaining Momentum
      11.4 Upsurge in the Number of Strategic Alliances
      11.5 Combination Therapy
      11.6 Co-pay and Assistance Programs by Vendors
      11.7 Increased R&D Activities: Pillars for Market Growth

12. Cystic Fibrosis Pipeline Analysis
      12.1 Pipeline Analysis by Phase of Development
      12.2 Pipeline Analysis by Key Players
      12.3 Pipeline Analysis by Geography
      12.4 Pipeline Analysis by Routes of Administration

13. Porter's Five Forces Analysis

14. Competitive Landscape
      14.1 Share of Major Players

15. Company Profiles
      15.1 Genentech, Inc. (A Member of the Roche Group)
      15.2 Novartis
      15.3 Vertex Pharmaceuticals Incorporated
      15.4 Abbott Laboratories
      15.5 Gilead Sciences, Inc.
      15.6 Johnson & Johnson
      15.7 Allergan plc
      15.8 GlaxoSmithKline
      15.9 Mylan N.V.
      15.10 Pharmaxis Ltd